Twist Bioscience Corporation $TWST Stock: Pictet Asset Management Holding SA Reduces Holdings

Pictet Asset Management Holding SA lessened its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 23.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,061 shares of the company’s stock after selling 25,206 shares during the period. Pictet Asset Management Holding SA owned 0.13% of Twist Bioscience worth $15,523,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of TWST. Abacus Wealth Partners LLC boosted its holdings in shares of Twist Bioscience by 4.3% in the 3rd quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock valued at $451,000 after purchasing an additional 96 shares in the last quarter. CenterBook Partners LP acquired a new stake in Twist Bioscience in the third quarter valued at approximately $388,000. Calamos Advisors LLC acquired a new position in shares of Twist Bioscience during the third quarter worth $5,072,000. Commonwealth Equity Services LLC acquired a new position in shares of Twist Bioscience during the third quarter worth $275,000. Finally, Integrity Alliance LLC. bought a new position in shares of Twist Bioscience in the 3rd quarter valued at $430,000.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Guggenheim lifted their price target on Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Leerink Partners upped their price target on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. Canaccord Genuity Group boosted their price objective on shares of Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Barclays lifted their target price on Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $153.00.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $114.22 on Friday. The stock has a market capitalization of $7.16 billion, a price-to-earnings ratio of -51.45 and a beta of 2.25. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock’s 50 day moving average price is $150.57 and its two-hundred day moving average price is $92.73.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $126.64 million during the quarter, compared to analysts’ expectations of $123.55 million. The firm’s revenue was up 26.7% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience Corporation will post -2.11 earnings per share for the current year.

Top Twist Bioscience Stories

Here are a few of the latest stories about TWST:

• Positive Sentiment: Fiscal fourth-quarter revenue rose 28% year over year to $126.6 million, ahead of analyst expectations. The quarterly loss of $0.32 per share was also narrower than estimates and improved from a $0.45 loss a year earlier. Article: Twist Bioscience Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Fiscal 2027 first-quarter revenue guidance of $130 million–$132 million topped the $126.3 million consensus estimate, indicating continued near-term growth. Article: Twist Bioscience Earnings and Guidance
• Negative Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million was only slightly above the $549 million consensus. Reports characterized the outlook as insufficient to satisfy investors, helping explain why the stock fell despite the quarterly beats. Article: Twist Bio Slips Despite Q4 Beat After Underwhelming FY27 Outlook

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 356,546 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $157.99, for a total transaction of $56,330,702.54. Following the completion of the sale, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 9,514 shares of Twist Bioscience stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the transaction, the insider owned 63,789 shares of the company’s stock, valued at $12,048,466.32. This trade represents a 12.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 495,279 shares of company stock valued at $80,489,387 over the last ninety days. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.